CHD1L and colorectal carcinoma: Our findings provide a strong foundation for the further investigation of CHD1L inhibition in combination with chemotherapy and targeted therapies, with the potential to improve survival rates in CRC patients resistant to current treatments and to expand therapeutic strategies across a broader range of cancers.